NCT03244241View on ClinicalTrials.gov

Basal-bolus Insulin Therapy Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study

PHASE4UnknownINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

April 1, 2017

Primary Completion Date

April 1, 2018

Study Completion Date

April 1, 2018

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Insulin Degludec 100 UNT/ML [Tresiba]

Basal-bolus insulin regime

Trial Locations (1)

2650

RECRUITING

Hvidovre University Hospital, Hvidovre

Sponsors

Collaborators (1)

Novo Nordisk A/S

All Listed Sponsors

collaborator

Novo Nordisk A/S

INDUSTRY

lead

Merete Bechmann Christensen

OTHER